Sign in / Join Now
ETFs & Funds
So, for those following, my total development biotech portfolio as of today: $
Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Add a reply...
Latest StockTalks »
people get ARQL breaking news and analysis by email alert.
Get email alerts on ARQL »
Get latest price
From other sites
ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
at TheStreet (Fri, 7:00AM)
ArQule Announces First Patient Dosed In Phase 1 Trial Of BTK Inhibitor, ARQ 531, For B-cell Malignancies
at TheStreet (Jul 11, 2017)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors
at TheStreet (Jun 26, 2017)
ArQule Presents Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of The European Hematology Association (EHA)
at TheStreet (Jun 23, 2017)
ArQule Announces First Patient Dosed In Company Sponsored Phase 1/2 Trial Of AKT Inhibitor, ARQ 092, For Rare Overgrowth Diseases
at TheStreet (Jun 7, 2017)